Laboratory of Biopharmaceutical Research, National Institute of Biomedical Innovation, 7-6-8 Saito-Asagi, Ibaraki, Osaka, 567-0085, Japan.
Cancer Med. 2013 Dec;2(6):972-7. doi: 10.1002/cam4.156. Epub 2013 Nov 7.
Eph receptor A10 (EphA10) is a valuable breast cancer marker that is highly expressed in breast cancer tissues by comparison with normal breast tissues, as we previously reported. However, the role of EphA10 expression in breast cancer is not well understood. Here, we have analyzed the expression of EphA10 at the mRNA- and protein-level in clinical breast cancer tissues and then evaluated the relationship with clinicopathological parameters for each sample. EphA10 mRNA expression was quantified by real-time polymerase chain reaction using complimentary DNA (cDNA) samples derived from breast cancer patients. Lymph node (LN) metastasis and stage progression were significantly correlated with EphA10 expression at the mRNA level (P = 0.0091 and P = 0.034, respectively). Furthermore, immunohistochemistry (IHC) staining of breast cancer tissue microarrays (TMAs) revealed that EphA10 expression at the protein level was also associated with LN metastasis and stage progression (P = 0.016 and P = 0.011, respectively). These results indicate that EphA10 expression might play a role in tumor progression and metastasis. Our findings will help elucidate the role of EphA10 in clinical breast cancer progression.
Eph 受体 A10（EphA10）是一种有价值的乳腺癌标志物，与正常乳腺组织相比，在乳腺癌组织中高度表达，正如我们之前报道的那样。然而，EphA10 表达在乳腺癌中的作用尚不清楚。在这里，我们分析了 EphA10 在临床乳腺癌组织中的 mRNA 和蛋白水平的表达，并评估了每个样本 EphA10 表达与临床病理参数之间的关系。通过来自乳腺癌患者的 cDNA 样本，使用实时聚合酶链反应定量 EphA10 mRNA 表达。淋巴结（LN）转移和分期进展与 EphA10 在 mRNA 水平的表达显著相关（P=0.0091 和 P=0.034，分别）。此外，对乳腺癌组织微阵列（TMA）的免疫组织化学（IHC）染色显示 EphA10 蛋白水平的表达也与 LN 转移和分期进展相关（P=0.016 和 P=0.011，分别）。这些结果表明 EphA10 表达可能在肿瘤进展和转移中发挥作用。我们的研究结果将有助于阐明 EphA10 在临床乳腺癌进展中的作用。
